| The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease M Kremenchutzky, GPA Rice, J Baskerville, DM Wingerchuk, GC Ebers Brain 129 (3), 584-594, 2006 | 568 | 2006 |
| The natural history of multiple sclerosis: a geographically based study: 5. The clinical features and natural history of primary progressive multiple sclerosis DA Cottrell, M Kremenchutzky, GPA Rice, WJ Koopman, W Hader, ... Brain 122 (4), 625-639, 1999 | 444 | 1999 |
| Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study B Banwell, L Krupp, J Kennedy, R Tellier, S Tenembaum, J Ness, ... The Lancet Neurology 6 (9), 773-781, 2007 | 414 | 2007 |
| Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring L Kappos, D Bates, G Edan, M Eraksoy, A Garcia-Merino, N Grigoriadis, ... The Lancet Neurology 10 (8), 745-758, 2011 | 374 | 2011 |
| Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial DS Goodin, AT Reder, GC Ebers, G Cutter, M Kremenchutzky, J Oger, ... Neurology 78 (17), 1315-1322, 2012 | 310 | 2012 |
| Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ... Neurology 89 (11), 1117-1126, 2017 | 275 | 2017 |
| The natural history of multiple sclerosis: a geographically based study: 7. Progressive–relapsing and relapsing–progressive multiple sclerosis: a re-evaluation M Kremenchutzky, D Cottrell, G Rice, W Hader, J Baskerville, W Koopman, ... Brain 122 (10), 1941-1950, 1999 | 262 | 1999 |
| Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ... Neurology 89 (11), 1107-1116, 2017 | 229 | 2017 |
| A pilot study of oral calcitriol (1, 25-dihydroxyvitamin D3) for relapsing–remitting multiple sclerosis DM Wingerchuk, J Lesaux, GPA Rice, M Kremenchutzky, GC Ebers Journal of Neurology, Neurosurgery & Psychiatry 76 (9), 1294-1296, 2005 | 219 | 2005 |
| Trial of minocycline in a clinically isolated syndrome of multiple sclerosis LM Metz, DKB Li, AL Traboulsee, P Duquette, M Eliasziw, G Cerchiaro, ... New England Journal of Medicine 376 (22), 2122-2133, 2017 | 199 | 2017 |
| The natural history of multiple sclerosis: a geographically based study: 8: familial multiple sclerosis GC Ebers, WJ Koopman, W Hader, AD Sadovnick, M Kremenchutzky, ... Brain 123 (3), 641-649, 2000 | 172 | 2000 |
| Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis A Bar-Or, MS Freedman, M Kremenchutzky, F Menguy-Vacheron, ... Neurology 81 (6), 552-558, 2013 | 146 | 2013 |
| The 11-year long-term follow-up study from the randomized BENEFIT CIS trial L Kappos, G Edan, MS Freedman, X Montalban, HP Hartung, B Hemmer, ... Neurology 87 (10), 978-987, 2016 | 145 | 2016 |
| Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage M Filippi, MA Rocca, E Pagani, N De Stefano, D Jeffery, L Kappos, ... Journal of Neurology, Neurosurgery & Psychiatry 85 (8), 851-858, 2014 | 139 | 2014 |
| Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study P O'Connor, G Comi, MS Freedman, AE Miller, L Kappos, JP Bouchard, ... Neurology 86 (10), 920-930, 2016 | 135 | 2016 |
| Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study FD Lublin, JD Bowen, J Huddlestone, M Kremenchutzky, A Carpenter, ... Multiple sclerosis and related disorders 3 (6), 696-704, 2014 | 127 | 2014 |
| Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial SA Morrow, JA Fraser, C Day, D Bowman, H Rosehart, M Kremenchutzky, ... JAMA neurology 75 (6), 690-696, 2018 | 107 | 2018 |
| The natural history of multiple sclerosis: a geographically based study: 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive … DA Cottrell, M Kremenchutzky, GPA Rice, W Hader, J Baskerville, ... Brain 122 (4), 641-647, 1999 | 104 | 1999 |
| Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15 L Kappos, J Kuhle, J Multanen, M Kremenchutzky, EV di Cantogno, ... Journal of Neurology, Neurosurgery & Psychiatry 86 (11), 1202-1207, 2015 | 97 | 2015 |
| Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial MS Freedman, JS Wolinsky, B Wamil, C Confavreux, G Comi, L Kappos, ... Neurology 78 (23), 1877-1885, 2012 | 97 | 2012 |
